


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


Claim 1. (Original): A compound of formula I




wherein

R<sub>1</sub> is C<sub>1-6</sub>alkyl optionally substituted by OH, C<sub>1-2</sub>alkoxy or 1 to 6 fluorine atoms; C<sub>2-6</sub>alkenyl; or C<sub>2-6</sub>alkynyl;


R<sub>2</sub> is a radical of formula a, b or c



a



b



c

wherein

R<sub>6</sub> C<sub>1-12</sub>alkyl optionally substituted by halogen, by an optionally substituted cycloalkyl, by an optionally substituted phenyl, by an optionally substituted heteroaryl, or by an optionally substituted heterocyclic residue, wherein the C<sub>1-12</sub>alkyl optionally is interrupted by one or more O or C=O; and wherein the phenyl, heteroaryl, cycloalkyl, and/or heterocyclic residue may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkyl substituted by 1 to 5 fluorine atoms; C<sub>1-4</sub>alkoxy; C<sub>1-4</sub>alkoxy substituted by 1 to 5 fluorine atoms; cyano; phenyl; and phenyl substituted by 1 to 5 substituents selected from hydroxy, halogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, and cyano;

R<sub>7</sub> is H, optionally substituted phenyl, optionally substituted heteroaryl, wherein the phenyl and/or heteroaryl independently may be substituted by 1 to 5 substituents selected from hydroxy; halogen; C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkyl substituted by 1 to 5 fluorine atoms; C<sub>1-4</sub>alkoxy; C<sub>1-4</sub>alkoxy substituted by 1 to 5 fluorine atoms; and cyano;

X is O, C=O, S or a bond;

Z is N or O;

R<sub>3</sub> is A-B-COOH wherein each of A and B, independently is a bond, C=O or CDE, wherein each of D and E, independently is H, halogen, C<sub>1-3</sub>alkyl, OH; with the proviso that A and B are not both C=O; and

each of R<sub>4</sub> and R<sub>5</sub>, independently, is H, C<sub>1-4</sub>alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl;


with the proviso that when R<sub>4</sub> is H, R<sub>5</sub> is H, R<sub>3</sub> is COOH, R<sub>2</sub> is a radical of formula a and R<sub>7</sub> is H,

i) either R<sub>1</sub> is CH<sub>2</sub>OH and XR<sub>6</sub> is a radical C<sub>1-12</sub>alkyl not substituted, then XR<sub>6</sub> is not para to (CH<sub>2</sub>)<sub>2</sub>-CR<sub>1</sub>R<sub>3</sub>(NR<sub>4</sub>R<sub>5</sub>);

ii) or R<sub>1</sub> is CH<sub>3</sub> and XR<sub>6</sub> is a radical OC<sub>1-12</sub>alkyl non substituted, then XR<sub>6</sub> is not meta to (CH<sub>2</sub>)<sub>2</sub>-CR<sub>1</sub>R<sub>3</sub>(NR<sub>4</sub>R<sub>5</sub>);

in free form or in salt form.

Claim 2. (Currently amended): A compound of formula II



wherein R<sub>4</sub> to R<sub>3</sub> and R<sub>5</sub>-R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>5</sub> are as defined in claim 1, and R'<sub>4</sub> is a protecting group, or a salt thereof.


Claim 3. (Currently amended): A compound according to claim 1 or claim 2 which is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

Claim 4. (Currently amended): A pharmaceutical composition containing a compound according to ~~any one of~~ claim 1 to 3 in free form or in a pharmaceutically acceptable salt form, together with one or more pharmaceutically acceptable diluents or carriers therefor.

Claims 5-6. (Canceled)

Claim 7. (Currently amended): A pharmaceutical combination comprising a compound according to ~~any one of~~ claim 1 to 3 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory and chemotherapeutic agents.

Claim 8. (Original): A process for the preparation of a compound according to claim 1, which process comprises removing the protecting group present in a compound of formula II




wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are as defined in claim 1, R'<sub>3</sub> is -A-B-COOR<sub>8</sub> wherein A and B are as defined in claim 1 and R<sub>8</sub> is a hydrolysable or hydrogenolysable group and R'<sub>4</sub> is an amino protecting group,

and, where required, converting the compounds of formula I obtained in free form into the desired salt form, or vice versa.

Claim 9. (Currently amended): A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a compound according to ~~any one of claim 1 to 3 in~~ free form or in a pharmaceutically acceptable salt form ~~or a pharmaceutical composition according to claim 4.~~


Claim 10. (New): The method of claim 9 wherein the compound is of formula II



wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  and  $\text{R}_5$  are as defined in claim 1, and  $\text{R}'_4$  is a protecting group, or a salt thereof.

Claim 11. (New): The method of claim 9 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

Claim 12. (New): The composition of claim 4 wherein the compound is of formula II




wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  and  $\text{R}_5$  are as defined are as defined in claim 1, and  $\text{R}'_4$  is a protecting group, or a salt thereof.

Claim 13. (New): The composition of claim 4 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

Claim 14. (New): A method of treatment or prevention of allograft rejection, autoimmune disease, graft versus host disease, inflammatory diseases, myocarditis, hepatitis, ischemia/reperfusion injury, hemorrhage shock, traumatic shock, angiogenesis, Alzheimer's disease, cancer, infectious diseases or senile dementia, comprising administering to said subject a therapeutically effective amount of a composition according to claim 4.


Claim 15. (New): The composition of claim 14 wherein the compound is of formula II



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined are as defined in claim 1, and  $R'_4$  is a protecting group, or a salt thereof.

Claim 16. (New): The method of claim 14 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.

Claim 17. (New): The pharmaceutical combination of claim 7 wherein the compound is of formula II



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_5$  are as defined are as defined in claim 1, and  $R'_4$  is a protecting group, or a salt thereof.

Claim 18. (New): The pharmaceutical combination of claim 7 wherein the compound is selected from (R)-3-Amino-5-(4-heptyloxy-phenyl)-3-methyl-pentanoic acid, (R)-4-Amino-6-(4-heptyloxy-phenyl)-4-methyl-hexanoic acid and (R)-2-Amino-4-(4-heptyloxy-phenyl)-2-methyl-butanoic acid.